ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.264,54
0,56%
S&P 500
5.469,30
0,39%
Dow Jones
39.112,16
-0,76%
Euro vs US Dollar
1,06887
-0,19%
Bitcoin
61.292,07
-0,84%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Akili Inc (AKLI)

  7. Akili Inc (AKLI) News

AKLI

Akili (AKLI)

Akili Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AKLI
DatumZeitQuelleÜberschriftSymbolFirma
18/06/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKLIAkili Inc
18/06/202422h01Business WireAkili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video GameNASDAQ:AKLIAkili Inc
03/06/202423h21Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:AKLIAkili Inc
29/05/202423h32Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:AKLIAkili Inc
29/05/202422h05Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:AKLIAkili Inc
29/05/202415h16Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:AKLIAkili Inc
29/05/202415h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKLIAkili Inc
29/05/202414h00Business WireVirtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health CompanyNASDAQ:AKLIAkili Inc
14/05/202422h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKLIAkili Inc
14/05/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKLIAkili Inc
14/05/202422h01Business WireAkili Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKLIAkili Inc
06/05/202423h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKLIAkili Inc
30/04/202414h00Business WireAkili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial ResultsNASDAQ:AKLIAkili Inc
06/03/202422h28Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AKLIAkili Inc
06/03/202422h11Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AKLIAkili Inc
06/03/202422h07Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AKLIAkili Inc
29/02/202422h01Business WireAkili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AKLIAkili Inc
27/02/202408h00Business WirePureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in JapanNASDAQ:AKLIAkili Inc
26/02/202415h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKLIAkili Inc
26/02/202414h47Business WireAkili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in JapanNASDAQ:AKLIAkili Inc
23/02/202423h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKLIAkili Inc
23/02/202423h28Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKLIAkili Inc
23/02/202413h57Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AKLIAkili Inc
21/02/202422h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKLIAkili Inc
21/02/202422h05Business WireAkili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance UpdatesNASDAQ:AKLIAkili Inc
05/01/202422h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKLIAkili Inc
20/12/202322h58Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKLIAkili Inc
18/12/202314h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKLIAkili Inc
18/12/202314h00Business WireEndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17NASDAQ:AKLIAkili Inc
08/12/202323h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKLIAkili Inc
 Showing the most relevant articles for your search:NASDAQ:AKLI

Kürzlich von Ihnen besucht

ASX
RIOLOD
USOTC
CRWRF
Craneware PLC Livingston (PK)
TSXV
VGS
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten